Anti-cancer therapies are the most targeted applications in nanomedicine, followed by neuroscience and drug delivery products
BUENOS AIRES, Argentina, March 1, 2016 /PRNewswire/ -- The remarkable progress made in medicine and wellness over the last ten years is partially due to the radical advances made in nanotechnology. This technology's core healthcare applications include nanomedicine, nanobiosensing, nano self-assembly and life sciences, especially in the areas of precision targeted therapies, high-sensitivity chips, nano arrays and next-generation biomarkers.
New analysis from Frost & Sullivan, Trends in Nanomedicine (http://www.frost.com/sublib/display-report.do?id=D6C0-01-00-00-00&src=PR), identified unprecedented levels of innovation in nanomedicine. There have been notable developments in diagnostics, therapeutics, companion diagnostics, regenerative medicine and many other applications that are linked to the concept of precision medicine.
For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/LA_PR_FValente_D6C0_01March16.
"New nano formulations for targeting tumors, soft nanomaterials for bone regeneration and implantable devices for localized delivery of drugs have all given a huge boost to precision medicine," said TechVision Industry Analyst Cecilia Van Cauwenberghe. "Other innovations such as nanostructured surfaces for biosensors, image-guided implantation of advanced neurostimulators, 3D nanomaterials for stem cell immobilization and intelligent bioactive materials will usher in a new era of healthcare."
Nanomedicine facilitates personalized medicine in many ways. For instance, nano-based diagnostic tests or nano-imaging diagnosis may aid in the stratification of patients and thereby, guarantee personalized, patient-centered therapy. In addition, they make clinical protocols simpler, more efficient and affordable.
The inventions in nanomedicine have mostly benefitted the areas of immuno-oncology, inflammation, neurological disorders, cardiovascular and metabolic disorders, hematology, respiratory and infectious diseases. At present, there are more than 200 nanomedicine products at various stages of clinical trials, and more than 150 commercially available solutions. This number will increase substantially in the next five years, along with the number of market entrants.
There have been parallel trends in biotechnology with the rollout of protein polymers from natural sources. These materials are finding considerable application in the construction of novel nanocarrier systems and the rational design of protein nanoparticles based on the behavior of nanoparticles in the tumor microenvironment.
Although the industry is buzzing with activity, many nanoplatforms developed for cancer therapy have not progressed past Phase II of clinical trials and very few have obtained Food and Drug Administration (FDA) approval. The heavy investments required for R&D and clinical trials, complexity of manufacturing and regulatory challenges has necessitated external funding, at least until the processes are standardized.
"Importantly, nanomedicine has been able to attract sizeable public and private investments due to the escalating prevalence of cancer, orthopedic, cardio/neurovascular and metabolic disorders, and an aging population," noted Van Cauwenberghe. "In addition to large pharmaceutical companies, nanotech-based companies are also demonstrating a keen interest in tapping the healthcare industry."
Trends in Nanomedicine, part of the TechVision (Health & Wellness) subscription, studies the emerging trends in nanomedicines on a global scale, through a detailed strategic assessment of the industry environment. Frost & Sullivan's expert analysts thoroughly examine disease diagnosis and therapies, regenerative medicine, drug delivery systems and health monitoring, among many other tools closely related to precision medicine.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Trends in Nanomedicine
Corporate Communications – Latin America
P: +54 11 4777 5300
F: +54 11 4777 5300
SOURCE Frost & Sullivan